Get the Stockscreener App
11.70
5.41%
0.60
After Hours:
11.70
Oric Pharmaceuticals Inc stock is traded at $11.70, with a volume of 1.04M.
It is up +5.41% in the last 24 hours and down -12.69% over the past month.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
See More
Previous Close:
$11.10
Open:
$11.3
24h Volume:
1.04M
Relative Volume:
0.61
Market Cap:
$1.31B
Revenue:
-
Net Income/Loss:
$-129.47M
P/E Ratio:
-7.7248
EPS:
-1.5146
Net Cash Flow:
$-114.08M
1W Performance:
+7.73%
1M Performance:
-12.69%
6M Performance:
+12.39%
1Y Performance:
+73.33%
1-Day Range:
$11.29
$11.99
1-Week Range:
$10.59
$11.99
52-Week Range:
$3.8951
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Name
Oric Pharmaceuticals Inc
Sector
Industry
Phone
(650) 388-5600
Address
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
11.70 | 1.24B | 0 | -129.47M | -114.08M | -1.5146 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Initiated | Piper Sandler | Overweight |
| Nov-20-25 | Initiated | Evercore ISI | Outperform |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Oct-31-24 | Initiated | Wells Fargo | Overweight |
| Sep-06-24 | Initiated | Stifel | Buy |
| Feb-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-22-23 | Initiated | Wedbush | Outperform |
| Mar-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-21-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-16-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Perform |
| Apr-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Mar-25-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-22-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-21 | Upgrade | Citigroup | Neutral → Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-13-20 | Initiated | Robert W. Baird | Outperform |
| Aug-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Citigroup | Neutral |
| May-19-20 | Initiated | Guggenheim | Buy |
| May-19-20 | Initiated | JP Morgan | Overweight |
| May-19-20 | Initiated | Jefferies | Buy |
View All
Oric Pharmaceuticals Inc Stock (ORIC) Latest News
After golden cross, Oric Pharmaceuticals, Inc. (ORIC)'s technical outlook is bright - MSN
Precision Trading with Oric Pharmaceuticals Inc. (ORIC) Risk Zones - Stock Traders Daily
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpWhat's Next? - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) Trading Down 6.7%Here's Why - MarketBeat
ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting - marketscreener.com
ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat - GlobeNewswire
Experimental prostate cancer drug targets treatment resistance in lab tests - Stock Titan
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Competitor Tazverik Withdrawal And Analyst Support - Sahm
ORIC PE Ratio & Valuation, Is ORIC Overvalued - Intellectia AI
Oric Pharmaceuticals, Inc. $ORIC Position Reduced by ArrowMark Colorado Holdings LLC - MarketBeat
ORIC Pharmaceuticals (ORIC) Is Down 15.1% After Peer Drug Withdrawal Triggers Safety ScrutinyWhat's Changed - Sahm
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), MindWalk Holdings (HYFT) and Erasca (ERAS) - The Globe and Mail
Integral Health Asset Management LLC Cuts Stock Position in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Oric Pharmaceuticals, Inc.Common Stock (NQ: ORIC - The Chronicle-Journal
Oric Pharmaceuticals (ORIC) Sees Opportunity Amid Market Dynamics - GuruFocus
Oric Pharmaceuticals' (ORIC) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
ORIC Pharmaceuticals Reiterates 'Buy' Rating with $25 Target by HC Wainwright | ORIC Stock News - GuruFocus
Why ORIC Pharmaceuticals (ORIC) Is Down 15.1% After Ipsen Pulls Tazverik Over Safety Concerns - Yahoo Finance
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Recent Share Price Volatility - Yahoo Finance
JPMorgan reiterates Overweight on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
Oric Pharmaceuticals celebrates Employee Appreciation Day with recognition initiatives - Traders Union
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 8.8%Here's Why - MarketBeat
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street’s Latest Biopharma Calls Explained - AOL.com
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained - 24/7 Wall St.
ORIC Shares Drop Amid Market Withdrawal Concerns - GuruFocus
Constructive Buy Thesis on ORIC Driven by Differentiated PRC2 Biology and Manageable Safety Profile for Rinzimetostat - TipRanks
March 2026 Cantor Fitzgerald Maintains Overweight on ORIC (ORIC) - Meyka
Oric Pharmaceuticals stock tumbles on Tazverik withdrawal By Investing.com - Investing.com India
ORIC Stock Recovers Amid Potential for Long-Term Success Despite Temporary Setback - GuruFocus
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap DownWhat's Next? - MarketBeat
Technical Reactions to ORIC Trends in Macro Strategies - Stock Traders Daily
Oric Pharmaceuticals stock tumbles on Tazverik withdrawal - Investing.com UK
Jones Trading reiterates Buy on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
ORIC Pharmaceuticals Shares Drop Following Ipsen's Drug Withdrawal - GuruFocus
After Golden Cross, Oric Pharmaceuticals, Inc. (ORIC)'s Technical Outlook is Bright - Finviz
ORIC Pharmaceuticals: Differentiated PRC2 Inhibitor Rinzimetostat Mitigates Sector Safety Overhang and Supports Buy Rating - TipRanks
After the Golden Cross, the technical perspective for Oric Pharmaceuticals, Inc. (ORIC) appears promising - Bitget
Is ORIC Pharmaceuticals Inc. stock positioned for digital transformation2026 Drop Watch & Reliable Breakout Stock Forecasts - Naître et grandir
Trend Report: What is ORIC Pharmaceuticals Inc.’s market positionGap Down & Entry Point Confirmation Signals - baoquankhu1.vn
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Oric Pharmaceuticals reports inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
ORIC Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Earnings Update And New Shelf Registration - simplywall.st
Oric Pharmaceuticals Launches New 2026 ATM Share Program - TipRanks
JPMorgan Chase & Co. Has $14.74 Million Position in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Is ORIC’s ESOP Shelf And Narrower Quarterly Loss Altering The Investment Case For ORIC (ORIC)? - simplywall.st
History Review: What is ORIC Pharmaceuticals Incs market position2025 Volatility Report & AI Enhanced Trading Alerts - baoquankhu1.vn
ORIC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Oric Pharmaceuticals Inc Stock (ORIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):